Trial Name: NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplaton as first line treatment of gastrointestional neuroendocrine carcinomas (ACTRN12616000958482).
Patients Involved: Adults with advanced and/or metastatic non-resectable gastrointestinal Neuroendocrine Carcinomas (NECs), including both small cell and large cell-NEC.
Treatment Given: nab-paclitaxel + carboplatin OR etoposide + carboplatin.
Rationale for Treatment: In Australia, the current standard chemotherapy treatment for neuroendocrine cancers is carboplatin plus etoposide. This is based on similarities with small cell lung cancer, however the effectiveness of this treatment for neuroendocrine cancers has never been investigated in randomised trials. Also, even if initial chemotherapy may be effective, the cancer often returns in the patient within months, so better treatments are needed. It is hoped that the findings of this study will show which treatment is most promising – a combination of carboplatin and etoposide chemotherapy, or carboplatin and paclitaxel chemotherapy - in improving outcomes for patients with advanced gastrointestinal neuroendocrine carcinoma. Furthermore, the NABNEC study will enhance our understanding of the biology and imaging features of NECs.
Recruitment: The trial opened in September 2016. The aim is to recruit 70 patients from 20 Australian sites over a 36 month period.
Sites Involved: As of 26 March 2018 a total of 19 participants have enrolled. 15 Australian sites are open to recruitment.
For additional information please go to:
All correspondence should be directed to the NABNEC Trial Coordinator – email@example.com.